Immunovant, Inc. IMVT announced positive initial data from the 600 mg multiple-ascending dose (MAD) portion of its early-stage study on its new pipeline candidate, IMVT-1402. The phase I study is ...
An engaging anime doesn't always need superpowered heroes and giant titans. Sometimes, you just need pulse-pounding street racing action, and that's something "Initial D" has done incredibly well over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results